IP Library Granted Patent US 11,352,343
Granted Patent B2
US 11,352,343 · App. 16/900,657 · Granted Jun 7, 2022

Urea derivatives and uses thereof

Inventors: Winston Zapanta Ong (Watertown, MA); Pawel Wojciech Nowak (Watertown, MA); John Thomas Feutrill (Watertown, MA); Jinsoo Kim (Watertown, MA)
Assignee: Kala Pharmaceuticals, Inc.
C07D403/10A61K9/0048A61K9/146A61K31/416C07D231/56C07D401/04C07D403/04C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,343
App. No.
16/900,657
Granted
Jun 7, 2022
Kind
B2
Abstract

The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

Claims (47)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof;

wherein:

X A is C;

X B is C;

X C is NH;

X D is N;

each instance of R A is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR A1 , —N(R A1 ) 2 , —SR A1 , —CN, —SCN, —C(═NR A1 )R A1 , —C(═NR A1 )OR A1 , —C(═NR A1 )N(R A1 ) 2 , —C(═O)R A1 , —C(═O)OR A1 , —C(═O)N(R A1 ) 2 , —NO 2 , —NR A1 C(═O)R A1 , —NR A1 C(═O)OR A1 , —NR A1 C(═O)N(R A1 ) 2 , —OC(═O)R A1 , —OC(═O)OR A1 , or —OC(═O)N(R A1 ) 2 , or two instances of R A are joined to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each instance of R A1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R A1 are joined to form substituted or unsubstituted heterocyclyl;

Ring Z is naphthalenyl;

each instance of R B is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR B1 , —N(R B1 ) 2 , —SR B1 , —CN, —SCN, —C(═NR B1 )R B1 , —C(═NR B1 )OR B1 , —C(═NR B1 )N(R B1 ) 2 , —C(═O)R B1 , —C(═O)OR B1 , —C(═O)N(R B1 ) 2 , —NO 2 , —NR B1 C(═O)R B1 , —NR B1 C(═O)OR B1 , —NR B1 C(═O)N(R B1 ) 2 , —OC(═O)R B1 , —OC(═O)OR B1 , or —OC(═O)N(R B1 ) 2 , or two instances of R B are joined to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each instance of R B1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R B1 are joined to form substituted or unsubstituted heterocyclyl;

R C is substituted or unsubstituted alkyl, a nitrogen protecting group, or of the formula:

Ring C is substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each instance of R C1 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR C1a , —N(R C1a ) 2 , —SR C1a , —CN, —SCN, —C(═NR C1a )R C1a , —C(═NR C1a )OR C1a , —C(═NR C1a )N(R C1a ) 2 , —C(═O)R C1a , —C(═O)OR C1a , —C(═O)N(R C1a ) 2 , —NO 2 , —NR C1a C(═O)R C1a , —NR C1a C(═O)OR C1a , —NR C1a C(═O)N(R C1a ) 2 , —OC(═O)R C1a , —OC(═O)OR C1a , —OC(═O)N(R C1a ) 2 , or a nitrogen protecting group when attached to a nitrogen atom, or two instances of R C1 are joined to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each instance of R C1a is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R C1a are joined to form substituted or unsubstituted heterocyclyl;

R D is hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

R E is hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

a is 0;

b is 0, 1, 2, 3, or 4; and

c is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

9. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

10. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

12. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

14. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

16. A pharmaceutical composition comprising a compound of claim 5 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

17. The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

18. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

20. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

21. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is suitable for topical administration to the eye of a subject.

Assignments (4)
CHANGE OF NAME Recorded Sep 21, 2023
From: KALA PHARMACEUTICALS, INC.
To: KALA BIO, INC.
Reel/Frame 065017/0488 →
FIRST AMENDMENT TO IP SECURITY AGREEMENT Recorded Dec 22, 2022
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 062205/0883 →
SECURITY INTEREST Recorded May 6, 2021
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 056168/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: ONG, WINSTON ZAPANTA; NOWAK, PAWEL WOJCIECH; FEUTRILL, JOHN THOMAS; KIM, JINSOO
To: KALA PHARMACEUTICALS, INC.
Reel/Frame 052932/0269 →
Continuity (9)
Division 16400672 · May 1, 2019
Continuation 16043007 · Jul 23, 2018
Continuation 15782743 · Oct 12, 2017
Continuation 15411485 · Jan 20, 2017
Division 14939727 · Nov 12, 2015
Division 14301653 · Jun 11, 2014
Provisional Application 61833853 · Jun 11, 2013
Provisional Application 61898720 · Nov 1, 2013
Related Publication 20200299272A1 · Sep 24, 2020